Abstract 936P
Background
Advanced HNSCC patients with platinum-refractory disease have limited treatment options and poor outcomes, especially in resource-constrained settings. Triple metronomic therapy, a low-dose continuous chemotherapeutic strategy, has shown promise in phase 2 trials but requires further validation. We aimed to evaluate triple OMCT's efficacy in improving overall survival (OS) compared to physician-choice chemotherapy (PCC).
Methods
In this phase 3 open-label study, 214 advanced HNSCC patients previously treated with platinum-based chemotherapy (October 2021-August 2022) were randomized 1:1 to receive triple OMCT (Arm A) with Methotrexate 9 mg/m2 PO weekly, Celecoxib 200 mg twice daily and erlotinib 150 mg daily, or PCC (Arm B), stratified by age and performance status. Primary endpoint was OS, with secondary endpoints including progression-free survival (PFS), Quality of Life (QoL) assessments, and safety. OS and PFS were analyzed using Kaplan-Meier and log-rank tests, with hazard ratios estimated by Cox proportional hazard models. QoL was assessed using EORTC QLQ-C30.
Results
Table: 936P
Baseline characteristics of the patients
Characteristics | Arm A (Triple OMCT) n (%) | Arm B (Physician Choice) n (%) | p-value (Chi-square) |
Age (in years) <60 60 or more | 86 (80.4) 21 (19.6) | 85 (79.4) 22 (20.6) | 0.865 |
Sex Female Male | 6 (5.6) 101 (94.4) | 4 (3.7) 103 (96.3) | 0.517 |
Baseline Hemoglobin level (gm/dL) ≤ 12 > 12 | 68 (63.6) 39 (36.4) | 78 (72.9) 29 (27.1) | 0.142 |
Comorbidities Yes No | 7 (6.5) 100 (93.5) | 16 (15.0) 91 (85.0) | 0.077 |
ECOG Performace Status 1 2 | 68 (63.6) 39 (36.4) | 62 (57.9) 45 (42.1) | 0.401 |
Site of Tumor Oral Cavity Others | 70 (65.4) 37 (34.6) | 71 (66.4) 36 (33.6) | 0.885 |
Most patients had ECOG PS 1 (60.7%) and tumor site in the oral cavity (65.9%). With a median follow-up of 11 months, the median OS was 9 months in Arm A and 5 months in Arm B (HR, 0.63; 95% CI, 0.47–0.83; p=0.00011). Median PFS was 4 months in Arm A and 2 months in Arm B (HR, 0.67; 95% CI, 0.52–0.87; p<0.0001). Multivariate analysis identified age, hemoglobin level, and comorbidity as significant OS prognostic factors. No significant QoL score differences were observed. Triple OMCT showed fewer grade 3 or higher adverse events than PCC (28.0% vs 39.3%, p=0.03).
Conclusions
Triple OMCT is an effective, safe treatment for advanced HNSCC patients previously treated with platinum-based chemotherapy, offering improved OS and tolerable side effects compared to physician-choice chemotherapy.
Clinical trial identification
Clinical Trial Registry-India CTRI/2021/09/036296.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Indian Cooperative Oncology Network (ICON) Trust.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
868P - A DNA methylation classifier to predict recurrence from clear surgical margins
Presenter: tsima Abou Kors
Session: Poster session 12
869P - Utilizing H&E images and digital pathology to predict response to buparlisib in SCCHN
Presenter: Denis Soulieres
Session: Poster session 12
870P - Dynamic cfHPV DNA changes during induction chemotherapy as an early indicator of treatment responsiveness for locally advanced head and neck cancer patients
Presenter: Yilin Cao
Session: Poster session 12
871P - Detection of circulating tumor DNA in operable loco-regionally advanced HPV-negative head and neck squamous cell carcinoma
Presenter: Ludivine Beaussire
Session: Poster session 12
872P - Prognostic value of pathological intratumor heterogeneity in patients with head and neck squamous cell carcinoma treated with upfront surgery
Presenter: Constance Lamy
Session: Poster session 12
873P - Identification of PIK3CA mutation as a novel predictor of efficacious immunotherapy in head and neck cancer
Presenter: Zongwen Sun
Session: Poster session 12
875P - Proteomic and phosphoproteomic profiling of HNSCC and the role of CDKs as potential drug targets
Presenter: Konrad Klinghammer
Session: Poster session 12
876P - Gene expression analysis in oral potentially malignant disorders (OPMD) with dysplasia identifies patients at high risk of malignant transformation
Presenter: Loris De Cecco
Session: Poster session 12
877P - ROS1 mutations as potential negative predictor for response of immunotherapy in patient with head and neck cancer
Presenter: Yong Yuan
Session: Poster session 12